

October 10-11, 2022 ➤ Baltimore, USA

November 17, 2022 ➤ Remote



10th
HEART FAILURE
GUIDELINES
FOR U M




BETTER UNDERSTAND

the heart failure
recommendations and
the decision making
process.

PRELIMINARY PROGRAM

*All talks are 5–8 mins. Focus is on extensive discussion.
Talks are to stimulate & kick-start these discussions.*



13:00–13:05 Welcome / Introductions *S. Anker – J. Butler*

13:05–13:40 Session 1 – Heart failure guideline process – Rules of engagement

- The general Guidelines process: all the same?! – *G. Filippatos*
- The issue of value statements in the US guidelines – *P. Heidenreich*
- Conflict of interest rules in the US and European guidelines: an update – *AJ Coats*
- Cases where guidelines recommendations differ from regulatory approval statements: drugs – *G Rosano*
- Cases where guidelines recommendations differ from regulatory approval statements: devices – *W Abraham*
- The perspective of the regulators
Discussion

13:40–14:20 Session 2 – What should be the basis for recommendations in our HF-GLs?

- Only the trial key outcomes – *J McMurray*
- What about subgroups results – *J Teerlink*
- What about meta analyses results – *M Vaduganathan*
- What about important surrogate end-points (better sleep in sleep apnea patients) – (TBC)
Discussion

14:20–15:00 Session 3 – Diagnosis

- What about GL recommendations for prognosticators – *K Adams*
- PCT and infection – *E Giannitsis*
- Focus on phenotype diagnoses: the ID example – *P Ponikowski*
General Discussion
- Are 3 “classes” of HF (by LVEF) the standard of care? or only 2? Or 4? or only 1? – *M Metra*
- LVEF: does it still matter to differentiate groups of HFREF patients? – *S Solomon*
General Discussion

15:00–15:30 Session 4 – Co-morbidities and enablement strategies part 1 (HK & ID)

- Treatment of hyperkalemia – *M Kosiborod*
- ID: The European Perspective – *E Jankowska*
- ID / Anemia: The US Perspective – *A Hernandez*
- Regulatory perspectives

15:30–16:00 Break

16:00–16:30 Session 5 – Co-morbidities and enablement strategies part 2 (obesity)

- Semaglutide – *S Anker*
- Tirzepatide – *M Packer*
- Bariatric surgery for obese patients with HF – TBC
General Discussion

16:30–17:30 Session 6 – Device for HF therapy part 1

- Neuromodulation – *W Abraham*
- CCM: New Developments – *J Butler*
- Intra-atrial shunt devices – *B Borlaug*
General Discussion
- How to phrase recommendations based on WinRatio results? – *J McMurray*
General Discussion

What would GLs require to recommend device therapy as an enabler of reaching GDMT target doses

17:30–18:00 Session 7 – Device for HF therapy part 2 focus on valvular heart disease

- Targeting FMR: MitraClip – *G Stone*
- Targeting FMR: Carillon – *R Starling*
General Discussion

18:00–19:00 Session 8 – OPEN SESSION

- OPEN TOPIC
- OPEN TOPIC

19:00–19:30 Ad hoc Q & A session (part 1)

October 11

08:30-15:00 Eastern time



10th
Heart Failure
Guidelines Forum
BALTIMORE, USA
2022

08:30 Welcome

08:30–09:45 Session 9 – SGLT2 i

- Treating HFrEF and of HFpEF: Dapa and Empa are the same. Should guidelines reflect that? – *J Ezekowitz*
- Dapa and Empa should not have exactly the same recommendation?! Open debate – *TBC*
- *General Discussion*
- What about Sotagliflozin – *S Verma*
- What about starting in hospital – is a special recommendation needed? – *I Piña*
- *General Discussion*

09:45–10:30 Session 10 – Additional candidates for foundational therapies

- Is Fineranone (new class of MRA) a foundational therapy: diabetic kidney disease – *B Pitt*
- Are there more than 4 foundational therapies: what about vericiguat – *J Butler*
- Are there more than 4 foundational therapies: what about OM – *J Teerlink*
- Sacubitril/valsartan: in USA 1A and Europe 1B? does it make sense? – *B Bozkurt*
- *Discussion*

10:30–10:45 Break

10:45–11:25 Session 11 – More on foundational therapies

- Should there be recommendations on the preferred order? – *D Bhatt*
- Should there be recommendations on the preferred time lines for titration steps? – *J McMurray*
- What is reasonable and should affordability matter (data from COAPT?) – *G Stone*
- *Discussion*

11:25–12:05 Session 12 – What about high heart rate, AF and arrhythmias?

- Rate versus rhythm control – *D Burkhoff*
- Dronedarone for HFpEF?! – *M Vaduganathan*
- Medications versus catheter post ablation – *N Marrouche*
- *Discussion*
- Open topics
- PVCs / PVC-induced or worsened HF / PVC ablation

12:05–12:35 Session 13 – Device for HF therapy part 3: focus on TR

- Targeting TR – *B Borlaug*
- Interventional therapies for HFpEF
- *Discussion*

12:35–13:10 Lunch session – The need for international implementation guidelines

13:10–13:45 Session 14 – remote care approaches

- OPEN TOPIC
- OPEN TOPIC
- OPEN TOPIC

13:45–14:05 Session 15 – Special populations

- Hypertrophic CM
- Amyloid
- *Discussion*

14:05–14:30 Q & A session (part 2)

14:30 Conclusion

Chairs



Prof. Andrew Coats

DM, DSc, MBA, AO

Immediate Past President, Heart Failure Association of the ESC, Academic Vice-President Monash-Warwick Alliance, Monash University, Melbourne, Australia, University of Warwick, Coventry, UK



Prof. Javed Butler

MD, MPH, MBA

Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi in Jackson, MS, USA.



Prof. Stefan Anker

MD, PhD, FESC

Professor of cardiology and Cachexia Research, Department of Cardiology Charité Campus Virchow-Klinikum Berlin, Germany



Prof. William Abraham

MD, FACP, FACC, FAHA, FESC, FRCPE

Professor of Medicine, Physiology, and Cell Biology College of Medicine, Distinguished Professor, Division of Cardiovascular Medicine, the Ohio State University, USA

Faculty

North America

- Kirkwood F. Adams
- Deepak L. Bhatt
- Barry A. Borlaug
- Biykem Bozkurt
- Daniel Burkhoff
- Justin Ezekowitz
- Paul A. Heidenreich
- Adrian Hernandez
- Mikhail N. Kosiborod
- Tammy Kindel
- JoAnn Lindenfeld
- Nassir F. Marrouche
- Milton Packer
- Ileana Piña
- Bertram Pitt
- Scott Solomon

- Lynne Stevenson
- Norman Stockbridge
- Gregg Stone
- John R. Teerlink
- Subodh Verma
- Muthiah Vaduganathan
- Shelley Zieroth
- Bram Zuckerman

Europe

- Gerasimos Filippatos
- Evangelos Giannitsis
- Ewa Jankowska
- John J. McMurray
- Marco Metra

- Piotr Ponikowski
- Giuseppe Rosano

Asia

- Vijay Chopra
- Hiroyuki Tsutsui
- Jian Zhang
- Yuhui Zhang